Qiagen N.V. (QGEN)

NYSE: QGEN · IEX Real-Time Price · USD
41.51
+0.06 (0.14%)
Dec 4, 2023, 4:00 PM EST - Market closed
0.14%
Market Cap 9.47B
Revenue (ttm) 1.96B
Net Income (ttm) 484.93M
Shares Out 228.04M
EPS (ttm) 2.12
PE Ratio 28.63
Forward PE 19.34
Dividend n/a
Ex-Dividend Date n/a
Volume 764,505
Open 41.43
Previous Close 41.45
Day's Range 41.26 - 41.67
52-Week Range 34.74 - 51.18
Beta 0.43
Analysts Buy
Price Target 50.50 (+21.66%)
Earnings Date Oct 30, 2023

About QGEN

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample mate... [Read more]

Sector Healthcare
IPO Date Jun 28, 1996
Employees 6,178
Stock Exchange NYSE
Ticker Symbol QGEN
Full Company Profile

Financial Performance

In 2022, Qiagen's revenue was $2.14 billion, a decrease of -4.82% compared to the previous year's $2.25 billion. Earnings were $575.66 million, an increase of 7.19%.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $50.5, which is an increase of 21.66% from the latest price.

Price Target
$50.5
(21.66% upside)
Analyst Consensus: Buy
Stock Forecasts

News

DNA Labs International solves significant cold cases with QIAGEN workflow for forensic genetic genealogy

QIAGEN's ForenSeq Kintelligence System recently used by DNA Labs International in the U.S. to solve unidentified remains case in Oregon and 51-year-old criminal investigation in Georgia // ForenSeq Ki...

4 days ago - GlobeNewsWire

QIAGEN launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for improved sample processing and RNA isolation

TissueLyser III bead mill instrument can be used to effectively disrupt samples such as bones, as well as animal and plant tissue to enable access to nucleic acids // TissueLyser III enhances QIAGEN p...

19 days ago - GlobeNewsWire

QIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers

Three new QIAcuity kits enhance digital PCR applications in biopharma research and food safety, ensuring precise quantification, increased sensitivity and cost-efficiency // QIAcuity Software 2.5 upda...

25 days ago - GlobeNewsWire

QIAGEN launches complete Sample to Insight workflow for microbiome research

Simplified and accelerated research workflow including high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis // Workflow enable...

4 weeks ago - GlobeNewsWire

QIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System

Partnership combines QIAGEN's QIAseq panels, CLC LightSpeed, and QCI Interpret software to support Element's AVITI System users in genomic analysis Element and QIAGEN are advancing genomic application...

4 weeks ago - PRNewsWire

QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER

Q3 2023: Net sales of $476 million (-5% at actual rates, -6% at constant exchange rates, CER); diluted EPS of $0.34 and adjusted diluted EPS of $0.50 // Net sales at CER of $470 million ahead of outlo...

5 weeks ago - GlobeNewsWire

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests // Combined strengths in assay development, clinical testing, and regulatory approvals offers pha...

5 weeks ago - GlobeNewsWire

QIAGEN N.V. to release results for Q3 2023 and hold webcast

Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023.

2 months ago - GlobeNewsWire

QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus

QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology a...

2 months ago - GlobeNewsWire

QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness

AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN's proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome...

2 months ago - GlobeNewsWire

QIAGEN's QuantiFERON solutions recommended for use by kidney specialists in Tunisia

TUNIS, Tunisia, Sept. 28, 2023 (GLOBE NEWSWIRE) -- QIAGEN today announced that the comprehensive QuantiFERON immune response blood tests have been recommended for use by clinicians in Tunisia to help ...

2 months ago - GlobeNewsWire

QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report

Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating and among the industry leaders with ISS-ESG rating // Environment: Net-zero target validated by...

2 months ago - GlobeNewsWire

QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits

New kits reduce use of plastics by up to 62% and cardboard by up to 58% compared to QIAGEN standard kits // Two additions to growing QIAwave portfolio: QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA...

2 months ago - GlobeNewsWire

QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook

Q2 2023: Net sales of $495 million (-4% at actual rates, -4% at constant exchange rates, CER); diluted EPS of $0.35 and adjusted diluted EPS of $0.51 // Net sales at CER of $497 million ahead of outlo...

4 months ago - GlobeNewsWire

QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines' AYVAKIT® (avapritinib) in gastrointestinal stromal tumors

QIAGEN's therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with unresectable or metastatic gastrointestinal stromal tumors positive for the PDGFRA D842V mutation who may b...

4 months ago - GlobeNewsWire

Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement

Hercules, Calif., and Venlo, the Netherlands, July 26, 2023 (GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announ...

4 months ago - GlobeNewsWire

Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement

HERCULES, Calif., & VENLO, the Netherlands--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the compa...

Other symbols: BIO
4 months ago - Business Wire

QIAGEN N.V. to release results for Q2 2023 and hold webcast

Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023.

4 months ago - GlobeNewsWire

QIAGEN expands range of digital PCR kits and services for the biopharma industry

New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers // Launch of CGT Viral Vector Lysis Kit enabling standardized workflow from cell lysa...

4 months ago - GlobeNewsWire

FBI approves QIAGEN's NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)

NDIS approval provides access to federal government funding for accredited public crime laboratories in the U.S. to implement next-generation sequencing (NGS) for routine casework // NGS-based ForenSe...

5 months ago - GlobeNewsWire

QIAGEN provides reminder on settlement mechanics of 2023 and 2024 convertible notes

Venlo, the Netherlands, June 16, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a notice (reiterating its notice to holders dated January 9, 2019) to ...

6 months ago - GlobeNewsWire

QIAGEN's QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening

First-of-its-kind systematic review on the clinical relevance of test values from the QuantiFERON-TB Gold Plus TB1 and TB2 blood collection tubes has been published // Study including 4,050 subjects h...

6 months ago - GlobeNewsWire

Danish National Genome Center selects QIAGEN for variant interpretation in oncology genome sequencing

Denmark one of the first countries to implement whole-genome sequencing (WGS) as a standard-of-care for oncology and to adopt QCI Interpret to support the national initiative // QCI Interpret to be us...

6 months ago - GlobeNewsWire

QIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolio

Q1 2023: Net sales of $485 million (-23% at actual rates, -20% at constant exchange rates, CER); diluted EPS of $0.37 and adjusted diluted EPS of $0.51 // Net sales at CER of $502 million ahead of out...

7 months ago - GlobeNewsWire

QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk

Venlo, the Netherlands, and Germantown, Maryland, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task...

7 months ago - GlobeNewsWire